Advanced Pharmacology NURS 6521 Study Notes
Here is a comprehensive set of detailed study notes for NURS 6521: Advanced Pharmacology at Walden University. These notes are organized by the standard 11-week module structure used in most sections of the course. They draw from the official course description, typical syllabus, required readings (commonly from texts like Lehne’s Pharmacotherapeutics for Advanced Practice Providers by Rosenthal & Burchum or Pharmacotherapeutics for Advanced Practice by Arcangelo et al.), and key learning outcomes.
Focus on the “Big Five” for every major drug class:
Mechanism of Action (MOA)
Indications
Contraindications / Precautions
Adverse Effects / Black Box Warnings
Key Interactions / Monitoring Parameters (labs, vital signs, patient education)
Always integrate patient-specific factors (age, genetics/pharmacogenomics, renal/hepatic function, pregnancy/lactation, comorbidities, adherence, cost) into decision-making.
Course Overview & Learning Outcomes
Course Description: This 5-credit, 11-week course builds a foundation in advanced pharmacology for APRNs. It emphasizes pharmacokinetics (what the body does to the drug), pharmacodynamics (what the drug does to the body), pharmacogenomics, and evidence-based prescribing across the lifespan for acute and chronic conditions. Key themes include safety, ethical/legal aspects of prescribing, drug interactions, monitoring, patient education, and non-pharmacologic adjuncts.
Core Learning Outcomes:
Evaluate impact of patient factors on PK/PD processes.
Analyze pharmacotherapeutic treatments for body system disorders and their effects on outcomes.
Apply decision-making strategies based on drug classification, indications, patient factors, and pathophysiology.
Evaluate ethical and legal implications of prescribing.
Grading (typical): Weekly Discussions (initial post + responses), Quizzes (Weeks 2, 3, 5, 8, 10), Case Study Assignments (e.g., Weeks 1, 4, 7, 9), Midterm (Week 6), Final Exam (Week 11).
Study Tip: Use case studies to practice selecting first-line therapy, alternatives, monitoring, and patient education. Review drug tables, prototypes, and high-alert medications frequently.
Week 1: Basic Pharmacotherapeutic Concepts / Ethical and Legal Aspects of Prescribing
Key Concepts:
Pharmacokinetics (ADME): Absorption (route, first-pass effect, bioavailability), Distribution (protein binding, volume of distribution, blood-brain barrier), Metabolism (CYP450 enzymes, phase I/II, genetic variations), Excretion (renal clearance, half-life, steady state).
Pharmacodynamics: Receptor theory (agonists, antagonists, partial agonists), dose-response curve, therapeutic index, potency vs. efficacy.
Pharmacogenomics: CYP2D6, CYP2C19, VKORC1 examples (e.g., warfarin, clopidogrel, codeine).
Patient Factors: Age (pediatric/geriatric changes), sex, ethnicity, diet, smoking, alcohol, comorbidities (renal/hepatic impairment), pregnancy categories (old A–X vs. new narrative), lactation.
Ethical/Legal: Informed consent, off-label use, DEA schedules (esp. II–V), state prescriptive authority, controlled substance regulations, documentation, error disclosure/nondisclosure.
Discussion Focus: Explain how PK/PD factors influence drug response in a specific patient scenario (e.g., elderly patient with polypharmacy or renal impairment).
Assignment Tip (Ethical & Legal Implications): Analyze a scenario (e.g., prescribing to a colleague’s family, refusing a controlled substance request, or off-label use). Cover legal (state board/DEA), ethical principles (beneficence, non-maleficence, autonomy, justice), strategies to mitigate risks, and references in APA.
High-Yield: “Five Rights” of administration + “rights” of delegation/prescribing. Be familiar with narrow therapeutic index drugs (e.g., digoxin, warfarin, lithium, phenytoin).
Week 2–3: Cardiovascular and Respiratory Systems
Cardiovascular (Week 2):
Hypertension: Thiazides, ACEIs/ARBs, CCBs (dihydropyridine vs. non-), beta-blockers, aldosterone antagonists. JNC 8 / ACC/AHA guidelines. First-line considerations by comorbidity (e.g., diabetes → ACEI/ARB).
Heart Failure: ACEI/ARB/ARNI, beta-blockers (carvedilol, metoprolol succinate), aldosterone antagonists, SGLT2 inhibitors, loop diuretics. HFrEF vs. HFpEF.
Dyslipidemia: Statins (HMG-CoA reductase inhibitors – monitor LFTs, CK), ezetimibe, PCSK9 inhibitors, fibrates, niacin.
Anticoagulation/Antiplatelets: Warfarin (monitor INR, vitamin K), DOACs (apixaban, rivaroxaban – renal dosing), aspirin, clopidogrel (CYP2C19), heparin (aPTT vs. anti-Xa).
Respiratory (Week 3):
Asthma/COPD: Short- vs. long-acting beta-agonists (SABA/LABA), anticholinergics (ipratropium/tiotropium), inhaled corticosteroids (ICS), combination inhalers (LABA/ICS), leukotriene modifiers (montelukast), biologics (omalizumab).
Key Issues: Stepwise therapy (GINA/GOLD guidelines), spacer use, adherence, oral thrush prevention with ICS, black box for LABA monotherapy.
Common Themes: Drug interactions (e.g., NSAIDs + ACEI = renal risk; beta-blockers + asthma caution), monitoring (BP, HR, electrolytes, lipids, INR), lifestyle modifications.
Assignment/Quiz Focus: Select therapy for a patient with hypertension + comorbidities or asthma exacerbation; justify with guidelines and monitoring plan.
Week 4: Gastrointestinal and Hepatobiliary Systems
Key Drug Classes:
GERD/PUD: PPIs (omeprazole – long-term risks: C. diff, fractures, hypomagnesemia), H2RAs (ranitidine – recall issues), antacids, sucralfate, misoprostol.
Nausea/Vomiting: 5-HT3 antagonists (ondansetron), NK1 antagonists (aprepitant), dopamine antagonists (metoclopramide – tardive dyskinesia risk), antihistamines (promethazine).
Diarrhea/Constipation: Loperamide, bulk-forming/osmotic/stimulant laxatives, methylnaltrexone (opioid-induced).
IBD: Aminosalicylates (mesalamine), corticosteroids, immunomodulators, biologics (anti-TNF).
Hepatobiliary: Drug-induced liver injury (acetaminophen toxicity – NAC antidote), statins caution, monitoring LFTs.
Case Study Tip: Develop a plan for a patient with nausea, vomiting, and diarrhea (e.g., “Patient HL”). Include stepwise therapy, alternatives if contraindicated, monitoring (electrolytes, renal function), and education on hydration/diet.
High-Yield: PPIs – shortest duration possible; acetaminophen max daily dose (3–4g); opioid-induced constipation prevention.
Week 5: Endocrine System
Key Topics:
Diabetes Mellitus: Biguanides (metformin – lactic acidosis risk, hold with contrast/renal impairment), sulfonylureas (hypoglycemia), TZDs (pioglitazone – heart failure risk), DPP-4 inhibitors, GLP-1 agonists (semaglutide – weight loss, GI side effects), SGLT2 inhibitors (canagliflozin – genital infections, DKA risk), insulin (basal-bolus, analogs, monitoring).
Thyroid: Levothyroxine (monitor TSH), antithyroid drugs (methimazole, PTU – agranulocytosis).
Osteoporosis: Bisphosphonates (alendronate – esophageal irritation, osteonecrosis risk), denosumab, teriparatide, calcium/vitamin D.
Adrenal: Corticosteroids (adrenal suppression with long-term use).
Monitoring: A1C, glucose, renal function (eGFR for metformin/SGLT2), weight, bone density.
Discussion Focus: Individualized therapy considering genetics, adherence, cost, and comorbidities.
Week 6: Neurological and Musculoskeletal Systems (Midterm Coverage)
Neurological:
Seizures: Phenytoin, carbamazepine, valproate, lamotrigine, levetiracetam – therapeutic levels, enzyme induction/inhibition.
Parkinson’s: Levodopa/carbidopa, dopamine agonists (pramipexole – impulse control), MAO-B inhibitors.
Alzheimer’s: Cholinesterase inhibitors (donepezil), memantine.
Migraine: Triptans (sumatriptan – vasoconstriction caution), CGRP antagonists, prophylactics (beta-blockers, topiramate).
Pain/Musculoskeletal:
NSAIDs (GI/renal/CV risks), acetaminophen, opioids (stewardship, naloxone), adjuvants (gabapentinoids, TCAs, SNRIs).
Muscle Relaxants: Cyclobenzaprine, baclofen.
Midterm Tip: Covers Weeks 1–6 heavily. Expect questions on MOA, selection by patient factors, interactions, and monitoring. Review prototypes and high-risk drugs.
Week 7: Psychological Disorders
Key Drug Classes:
Depression/Anxiety: SSRIs (fluoxetine, sertraline – sexual dysfunction, serotonin syndrome), SNRIs (venlafaxine – withdrawal, BP increase), TCAs (overdose risk), MAOIs (tyramine crisis), benzodiazepines (short-term only – dependence).
Bipolar: Lithium (narrow index, monitor levels/renal/thyroid, toxicity signs), valproate, lamotrigine, atypical antipsychotics.
Schizophrenia/Psychosis: Typical (haloperidol – EPS) vs. atypical antipsychotics (olanzapine, quetiapine – metabolic syndrome, QT prolongation).
ADHD: Stimulants (methylphenidate, amphetamines – abuse potential, growth monitoring), non-stimulants (atomoxetine).
Black Box Warnings: Antidepressants – suicidality in young adults; antipsychotics – elderly dementia mortality.
Assignment Focus: Develop a psychopharmacologic plan with rationale, monitoring for side effects, and patient education.
Week 8: Women’s and Men’s Health / Reproductive System
Topics:
Contraception: Combined oral contraceptives (risks: VTE, stroke), progestin-only, IUDs, implants, emergency (levonorgestrel, ulipristal).
Hormone Therapy: Menopausal HRT (risks/benefits), testosterone replacement.
Erectile Dysfunction: PDE5 inhibitors (sildenafil – nitrates contraindication, vision/hearing loss).
BPH: Alpha-blockers (tamsulosin – orthostasis), 5-alpha reductase inhibitors (finasteride).
Pregnancy/Lactation: Teratogens (e.g., ACEIs, statins, valproate), FDA categories, safe drugs (e.g., acetaminophen, certain antibiotics).
Considerations: Drug effects on fertility, pregnancy categories, breastfeeding compatibility.
Week 9: Infectious Diseases and Antimicrobial Therapy
Key Principles: Antibiotic stewardship, mechanisms of resistance, culture-directed therapy when possible.
Antibacterials: Beta-lactams (penicillins, cephalosporins – cross-reactivity), macrolides, fluoroquinolones (black box: tendon rupture, aortic issues, QT), tetracyclines, sulfonamides, vancomycin (red man, nephrotoxicity), aminoglycosides (ototoxicity/nephrotoxicity).
Antivirals: Acyclovir, oseltamivir, antiretrovirals (HIV – adherence critical).
Antifungals: Azoles (CYP inhibition), amphotericin B (nephrotoxic).
Common Infections: UTI (nitrofurantoin, TMP-SMX), pneumonia (community-acquired guidelines), skin/soft tissue, TB.
Quiz/Assignment: Select appropriate antimicrobial with rationale, duration, and monitoring for resistance/adverse effects.
Week 10: Hematologic, Oncologic, Immunologic Systems & Special Populations
Topics:
Anemias: Iron, B12/folate, erythropoiesis-stimulating agents (ESAs – CV risks).
Anticoagulants (review).
Chemotherapy Basics: Cell-cycle specific vs. nonspecific, common toxicities (myelosuppression, nausea, alopecia), supportive care.
Immunosuppressants: Corticosteroids, calcineurin inhibitors (tacrolimus – levels), biologics.
Vaccines: Schedules, contraindications, live vs. inactivated.
Special Populations: Pediatric (weight-based, off-label), geriatric (start low/go slow, Beers Criteria), pregnancy, renal/hepatic impairment dosing.
Week 11: Course Synthesis & Final Exam
Integrate concepts across systems (polypharmacy, deprescribing, drug-drug interactions via CYP450 or QT prolongation).
Emerging therapies, cost-effectiveness, patient adherence strategies.
Final Exam: Comprehensive (often 100 questions). Review all modules, focus on application to case scenarios.
General Study Strategies for Success in NURS 6521
Create drug comparison tables (e.g., antihypertensives by comorbidity).
Use mnemonics for side effects (e.g., “Hot as a hare, dry as a bone…” for anticholinergics).
Practice with Shadow Health or similar simulations if available.
For assignments: Always include rationale linked to guidelines/pathophysiology, alternatives, monitoring plan, patient education, and references (APA 7th).
High-alert areas: Narrow therapeutic index drugs, black box warnings, pregnancy risks, geriatric considerations, opioid stewardship.
Review frequently: CYP450 inducers/inhibitors, renal dosing adjustments, therapeutic drug monitoring levels.
These notes provide a solid framework. Supplement with your specific syllabus, required readings, weekly media, and Walden library resources for the most current guidelines (e.g., ADA for diabetes, GOLD for COPD).
Collepals.com Plagiarism Free Papers
Are you looking for custom essay writing service or even dissertation writing services? Just request for our write my paper service, and we'll match you with the best essay writer in your subject! With an exceptional team of professional academic experts in a wide range of subjects, we can guarantee you an unrivaled quality of custom-written papers.
Get ZERO PLAGIARISM, HUMAN WRITTEN ESSAYS
Why Hire Collepals.com writers to do your paper?
Quality- We are experienced and have access to ample research materials.
We write plagiarism Free Content
Confidential- We never share or sell your personal information to third parties.
Support-Chat with us today! We are always waiting to answer all your questions.
